Business
Inspira™ Technologies Performed HYLA™ Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies
The study team included leading ICU and respiratory specialists from Company's Scientific Advisory Board RA'ANANA, Israel, Sept. 7, 2022 /PRNewswire/ --
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"The study team included leading ICU and respiratory specialists from Company's Scientific Advisory Board\nRA'ANANA, Israel, Sept. 7, 2022 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the \"Company\" or \"Inspira Technologies\"), a groundbreaking respiratory support technology company, announces the completion of an animal study that was conducted at Lahav C.R.O (contract research organization) by leading intensive care unit, or ICU, and respiratory specialists, who are members of Inspira's Scientific Advisory Board. The completion of the animal study is an additional important step toward initiating human studies using the HYLA™ blood sensor.\n\n \n \n \n \n \n \n\n \nDuring an animal study, the HYLA™ blood sensor performed measurements of blood parameters with results being compared to numerous blood samples taken and analyzed using a routine blood gas analyzer, which is considered the standard of care used by hospitals today. The HYLA™ blood sensor is a non-invasive device, designed to provide continuous real-time measurements, overcoming the disadvantages of standard blood gas analysis machines that require blood to be drawn and cannot provide a continuous display of data indicating the patient's condition in real-time. These important characteristics of the HYLATM blood sensor may be vital in providing immediate alerts of sudden changes in a patient's condition and may reduce risks, complications, and costs.\nThe animal study was performed following prior successful ex-vivo data obtained with the HYLA™ blood sensor in the Company's laboratory. The lab results, accompanied by the encouraging animal study data, are important steps toward human studies.\nInspira Technologies OXY B.H.N. Ltd.\nInspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (Inspira™ ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.\nFor more informa...